Michael Kaufmann

Michael Kaufmann

Auto-generated profile, based on publicly available information

Michael Kaufmann

Chair for Biochemistry and Molecular Medicine, Division of Functional Genomics, Witten/Herdecke University, Witten and Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, Witten - Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in Journal of Circulating Biomarkers
Verified
Journal Article
Open access
PDF file
JHJonas Holdmann
Jonas Holdmann
LMLukas Markert
Lukas Markert
CKClaudia Klinger
Claudia Klinger
MKMichael Kaufmann
Michael Kaufmann
KSKarin Schork
Karin Schork
ASAndreas Savelsbergh
Andreas Savelsbergh
Introduction: Prostate cancer (PCa) is the second most frequently diagnosed cancer and the fifth most cancer-related cause of death worldwide. Various tools are used in the diagnosis of PCa, such as the Prostate-Specific Antigen (PSA) value or digital rectal examination. A final differentiation from benign prostate diseases such as benign prostatic hyperplasia (BPH) can often only be made by a transrectal prostate biopsy. This procedure carries post-procedural complications for the patients and may lead to hospitalization. Urinary exosomes contain unique components, such as microRNAs (miRNAs) with information about their original tissue. As miRNAs appear to play a role in the development of PCa, they might be useful to develop procedures that could potentially make transrectal biopsies avoidable in certain situations. Methods: The current study aimed to investigate whether miRNAs from urinary exosomes can be used to differentiate PCa from BPH. For this purpose, urine samples from 28 patients with PCa and 25 patients with BPH were collected and analysed using next-generation sequencing to obtain expression profiles. Results and conclusion: The two miRNAs hsa-miR-532-3p and hsa-miR-6749-5p showed a significant differential expression within the group of patients with PCa in a training subset of the data containing 32 patients. They were further validated on the independent test data subset containing 20 patients. Additionally, a machine learning algorithm was used to generate a miRNA pattern to distinguish the two disease entities. Both approaches seem to be suitable for the search of alternative diagnostic tools for the differentiation of benign and malignant prostate diseases.